» Authors » Hidekazu Nishikii

Hidekazu Nishikii

Explore the profile of Hidekazu Nishikii including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 72
Citations 1047
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Uehara A, Nishikii H, Suehara Y, Matsuoka R, Nanmoku T, Makishima K, et al.
Rinsho Ketsueki . 2025 Feb; 65(11):1368-1374. PMID: 39935223
A 64-year-old man was diagnosed with diffuse large B-cell lymphoma (DLBCL). He achieved complete remission after R-CHOP therapy, but experienced relapse as lymphoplasmacytic lymphoma (LPL) 4 years after initial treatment....
2.
Yui R, Nagaya S, Yasuda I, Togashi T, Kikuchi Y, Saito K, et al.
Int J Hematol . 2025 Feb; PMID: 39928218
Hereditary protein C (PC) deficiency is an inherited thrombophilic disorder caused by variants in the PC gene (PROC). We identified a novel PROC variant, c.302G>T, p.Cys101Phe (C101F), in a patient...
3.
Shima M, Suzuki N, Nishikii H, Amano K, Ogawa Y, Kobayashi R, et al.
Thromb Haemost . 2024 Aug; PMID: 39134043
Background:  Primary analysis of the phase III AGEHA study suggested a favorable benefit-risk profile for emicizumab prophylaxis in patients with acquired hemophilia A (PwAHA); however, only patients undergoing immunosuppressive therapy...
4.
Shiomi A, Kaneko T, Nishikawa K, Tsuchida A, Isoshima T, Sato M, et al.
Nat Commun . 2024 May; 15(1):3812. PMID: 38760380
The molecular system regulating cellular mechanical properties remains unexplored at single-cell resolution mainly due to a limited ability to combine mechanophenotyping with unbiased transcriptional screening. Here, we describe an electroporation-based...
5.
Yamazaki S, Mabuchi Y, Kimura T, Suto E, Hisamatsu D, Naraoka Y, et al.
Stem Cell Reports . 2024 Mar; 19(3):414-425. PMID: 38428413
Myeloid cells, which originate from hematopoietic stem/progenitor cells (HSPCs), play a crucial role in mitigating infections. This study aimed to explore the impact of mesenchymal stem/stromal cells (MSCs) on the...
6.
Momose H, Kurita N, Nishikii H, Yusa N, Yokoyama K, Shimizu E, et al.
Rinsho Ketsueki . 2024 Feb; 65(1):35-40. PMID: 38311387
A 64-year-old woman presented with fine motor impairment in both hands. MRI revealed a contrast-enhanced lesion in the medulla oblongata. Lymphoid cells with abnormal blebs were observed and a CD4/CD8...
7.
Maruyama Y, Nishikii H, Kurita N, Sakamoto T, Hattori K, Suehara Y, et al.
Blood Cells Mol Dis . 2024 Jan; 105:102820. PMID: 38199143
Background: Haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) with post-transplant cyclophosphamide (PTCy) is an important therapeutic option for patients lacking an HLA-matched donor. However, the significance of CD34 cell dose...
8.
Ishitsuka K, Nishikii H, Kimura T, Sugiyama-Finnis A, Yamazaki S
Exp Hematol . 2023 Dec; 131:104138. PMID: 38151170
Human hematopoietic stem cells (HSCs) are widely used as a cellular source for hematopoietic stem cell transplantation (HSCT) in the clinical treatment of hematological malignancies. After transplantation therapy, delays in...
9.
Kurita N, Nishikii H, Maruyama Y, Suehara Y, Hattori K, Sakamoto T, et al.
Ann Hematol . 2023 Aug; 102(10):2895-2902. PMID: 37589942
Graft failure and delayed hematopoietic recovery are the major limitations of cord-blood transplantation (CBT). Romiplostim, a thrombopoietin-receptor agonist, promotes megakaryopoiesis and multilineage hematopoiesis in aplastic anemia. The decreased number of...
10.
Sakamoto T, Obara N, Maruyama Y, Kato T, Kurita N, Hattori K, et al.
Eur J Haematol . 2023 Aug; 111(5):768-776. PMID: 37549934
Objectives: Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A is the standard treatment for aplastic anemia (AA). However, the efficacy of repeated IST with rabbit ATG (rATG) as...